Related Experiment Videos
Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy
Kimberly A Dornbrook-Lavender1, John A Pieper
1Department of Pharmacotherapy, University of North Carolina at Chapel Hill School of Pharmacy, Chapel Hill, NC 27599-7360, USA. kadlav@unc.edu
Insights
Statin therapy benefits coronary heart disease (CHD) patients, particularly those with specific gene variants. Genotyping may personalize statin treatment for improved cardiovascular event reduction.
Area of Science:
- Cardiology
- Pharmacogenomics
- Genetics
Background:
- Current coronary heart disease (CHD) prevention focuses on traditional risk factors like hypertension, smoking, and cholesterol, emphasizing low-density lipoprotein cholesterol (LDL-C) reduction.
- Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) reduce cardiovascular events, but their efficacy varies, suggesting additional mechanisms beyond LDL-C lowering.
Purpose of the Study:
- To investigate whether genetic variations influence patient response to statin therapy for CHD prevention.
- To explore the potential of pharmacogenomics in optimizing statin treatment strategies.
Main Methods:
- Retrospective analysis of statin trial data.
- Evaluation of associations between polymorphic candidate genes and clinical/metabolic response to statins.
- Comparison of statin efficacy in patients with variant versus wild-type genotypes.
Main Results:
- Statin therapy improves lipid profiles in all patients.
- Individuals with high-risk variant genotypes showed preferential benefits from statin therapy compared to wild-type genotypes.
- Specific genes analyzed include apolipoprotein E, stromelysin-1, beta-fibrinogen, cholesteryl ester transfer protein, lipoprotein lipase, hepatic lipase, and platelet glycoprotein III.
Conclusions:
- Genetic factors may predict individual response to statin therapy.
- Determining patient genotype could personalize statin treatment for enhanced cardiovascular risk reduction.
- Further prospective studies in genotyped populations are needed to validate these findings.
Abstract:
Current strategies for both the primary and secondary prevention of coronary heart disease (CHD) focus on the traditional risk factors, such as hypertension, smoking cessation, and cholesterol, as the primary determinants of the cardiac risk profile, with particular emphasis on the reduction of low-density lipoprotein cholesterol (LDL-C) to targeted goal levels as endorsed by the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII). Large primary and secondary prevention trials with the hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have demonstrated varying reductions in cardiovascular events associated with similar changes in LDL-C levels, suggesting statins may possess additional beneficial effects on other risk factors. Retrospective analyses of many statin trials have evaluated the association between several polymorphic candidate genes (apolipoprotein E, stromelysin-1, beta-fibrinogen, cholesteryl ester transfer protein, lipoprotein lipase, hepatic lipase, and platelet glycoprotein III) which have been identified as predictors of disease severity and both metabolic and clinical response to statin therapy. These results suggest that statin therapy improves plasma lipid profiles in all patients, but preferentially benefits individuals who carry a high risk, variant genotype for these risk factors as compared to individuals with the wild-type genotype. These observations suggest that determining individual patient genotype may be useful in optimizing the benefits of statin therapy. These hypothesis-generating data need to be prospectively evaluated in genotyped patients.